Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method

Human Gene Therapy

Volumn 22, Issue 2, 2011, Pages 155-165

  Chulay, Jeffrey D ^a   Ye, Guo Jie ^a   Thomas, Darby L ^a   Knop, David R ^a   Benson, Janet M ^b   Hutt, Julie A ^b   Wang, Gensheng ^b   Humphries, Margaret ^c   Flotte, Terence R ^c  

^a APPLIED GENETIC TECHNOLOGIES CORPORATION   (United States)

^b Lovelace Biomedical and Environmental Research Institute   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; FEMALE; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; SKELETAL MUSCLE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANALYSIS OF VARIANCE; ANIMALS; CELLS, CULTURED; DEPENDOVIRUS; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; PLASMIDS; SIMPLEXVIRUS; TRANSFECTION;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS; SIMPLEXVIRUS;

EID: 79951817601     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.118     Document Type: Article

References (31)

1. Bernstein, D.I., Aoki, F.Y., Tyring, S.K., Stanberry, L.R., St-Pierre, C., Shafran, S.D., Leroux-Roels, G., Van Herck, K., Bollaerts, A., and Dubin, G.; GlaxoSmithKline Herpes Vaccine Study Group. (2005). Safety and immunogenicity of glyco-protein D-adjuvant genital herpes vaccine. Clin. Infect. Dis. 40, 1271-1281. (Pubitemid 40570236)
2. Brantly, M.L., Wittes, J.T., Vogelmeier, C.F., Hubbard, R.C., Fells, G.A., and Crystal, R.G. (1991). Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 100, 703-708.
3. Brantly, M.L., Spencer, L.T., Humphries, M., Conlon, T.J., Spencer, C.T., Poirier, A., Garlington, W., Baker, D., Song, S., Berns, K.I., Muzyczka, N., Snyder, R.O., Byrne, B.J., and Flotte T.R. (2006). Phase I trial of intramuscular injection of a re-combinant adeno-associated virus serotype 2 alpha-1 anti-trypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 17, 1177-1186. (Pubitemid 44975135)
4. Brantly, M.L., Chulay, J.D., Wang, L., Mueller, C., Humphries, M., Spencer, L.T., Rouhani, F., Conlon, T.J., Calcedo, R., Betts, M.R., Spencer, C., Byrne, B.J., Wilson, J.M., and Flotte, T.R. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. U.S.A. 106, 16363-16368.
5. Chao, H., Monahan, P.E., Liu, Y., Samulski, R.J., and Walsh, C.E. (2001). Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol. Ther. 4, 217-222. (Pubitemid 32851285)
6. Corey, L., Langenberg, A.G., Ashley, R., Sekulovich, R.E., Izu, A.E., Douglas, J.M., Jr., Handsfield, H.H., Warren, T., Marr, L., Tyring, S., DiCarlo, R., Adimora, A.A., Leone, P., Dekker, C.L., Burke, R.L., Leong, W.P., and Straus, S.E. (1999). Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282, 331-340. (Pubitemid 29350487)
7. Crystal, R.G., Brantly, M.L., Hubbard, R.C., Curiel, D.T., States, D.J., and Holmes, M.D. (1989). The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest 95, 196-208. (Pubitemid 19026126)
8. Davidoff, A.M., Ng, C.Y., Zhou, J., Spence, Y., and Nathwani, A.C. (2003). Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102, 480-488. (Pubitemid 36841964)
9. Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. As-soc. 50, 1096-1121.
10. Dunnett, C.W. (1980). Pairwise multiple comparisons in the unequal variance case. J. Am. Stat. Assoc. 75, 796-800.
11. Flotte, T.R., Conlon, T.J., Poirier, A., Campbell-Thompson, M., and Byrne, B.J. (2007). Preclinical characterization of a re-combinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites. Hum. Gene Ther. 18, 245-256. (Pubitemid 46626463)
12. Gao, G.P., Alvira, M.R., Wang, L., Calcedo, R., Johnston, J., and Wilson, J.M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859. (Pubitemid 34994488)
13. Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J.A. (1998). Novel tools for production and purification of recombi-nant adenoassociated virus vectors. Hum. Gene Ther. 9, 2745-2760. (Pubitemid 29027018)
14. Hauck, B., and Xiao, W. (2003). Characterization of tissue tro-pism determinants of adeno-associated virus type 1. J. Virol. 77, 2768-2774. (Pubitemid 36222804)
15. Kang, W., Wang, L., Harrell, H., Liu, J., Thomas, D.L., Mayfield, T.L., Scotti, M.M., Ye, G.J., Veres, G., and Knop, D.R. (2009). An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther. 16, 229-239.
16. Liqun Wang, R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV sero-type and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81-87.
17. Lu, Y., Choi, Y.K., Campbell-Thompson, M., Li, C., Tang, Q., Crawford, J.M., Flotte, T.R., and Song, S. (2006). Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector. J. Gene Med. 8, 730-735.
18. Manno, C.S., Chew, A.J., Hutchison, S., Larson, P.J., Herzog, R.W., Arruda, V.R., Tai, S.J., Ragni, M.V., Thompson, A., Ozelo, M., Couto, L.B., Leonard, D.G., Johnson, F.A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A.W., Kay, M.A., High, K.A., and Glader, B. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972. (Pubitemid 36857981)
19. Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P.K., Nakai, H., Chew, A., Leonard, D., Wright, J.F., Lessard, R.R., Sommer, J.M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H.C., High, K.A., and Kay, M.A. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347. (Pubitemid 43355084)
20. Miller, J., and Ulrich, R. (2001). On the analysis of psychometric functions: the Spearman-Karber method. Percept. Psychophys. 63, 1399-1420. (Pubitemid 33610264)
21. Mochizuki, S., Mizukami, H., Ogura, T., Kure, S., Ichinohe, A., Kojima, K., Matsubara, Y., Kobayahi, E., Okada, T., Hoshika, A., Ozawa, K., and Kume, A. (2004). Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther. 11, 1081-1086. (Pubitemid 39023112)
22. Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791-801. (Pubitemid 34033377)
23. Rocke, D.M., and Durbin, B. (2003). Approximate variance-stabilizing transformations for gene-expression microarray data. Bioinformatics 19, 966-972. (Pubitemid 36675817)
24. Silverman, E.K., and Sandhaus, R.A. (2009). Clinical practice. Alpha1-antitrypsin deficiency. N. Engl. J. Med. 360, 2749-2757.
25. Song, S., Morgan, M., Ellis, T., Poirier, A., Chesnut, K., Wang, J., Brantly, M., Muzyczka, N., Byrne, B.J., Atkinson, M., and Flotte, T.R. (1998). Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl. Acad. Sci. U.S.A. 95, 14384-14388. (Pubitemid 28549376)
26. Song, S., Embury, J., Laipis, P.J., Berns, K.I., Crawford, J.M., and Flotte, T.R. (2001). Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of re-combinant adeno-associated virus (rAAV) vectors. Gene Ther. 8, 1299-1306. (Pubitemid 32834298)
27. Stanberry, L.R., Spruance, S.L., Cunningham, A.L., Bernstein, D.I., Mindel, A., Sacks, S., Tyring, S., Aoki, F.Y., Slaoui, M., Denis, M., Vandepapeliere, P., and Dubin, G. (2002). Glyco-protein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347, 1652-1661. (Pubitemid 35340783)
28. Thomas, D.L., Wang, L., Niamke, J., Liu, J., Kang, W., Scotti, M.M., Ye, G.J., Veres, G., and Knop, D.R. (2009). Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum. Gene Ther. 20, 861-870.
29. Virella-Lowell, I., Zusman, B., Foust, K., Loiler, S., Conlon, T., Song, S., Chesnut, K.A., Ferkol, T., and Flotte, T.R. (2005). Enhancing rAAV vector expression in the lung. J. Gene Med. 7, 842-850. (Pubitemid 41015532)
30. Xiao, W., Chirmule, N., Berta, S.C., McCullough, B., Gao, G., and Wilson, J.M. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73, 3994-4003. (Pubitemid 29189844)
31. Xu, F., Sternberg, M.R., Kottiri, B.J., McQuillan, G.M., Lee, F.K., Nahmias, A.J., Berman, S.M., and Markowitz, L.E. (2006). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296, 964-973. (Pubitemid 44285373)